Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells by unknown
Brief Definitive Report 
INTERLEUKIN  1  (IL-1)  INDUCES  BIOSYNTHESIS  AND  CELL 
SURFACE  EXPRESSION  OF  PROCOAGULANT  ACTIVITY  IN 
HUMAN  VASCULAR  ENDOTHELIAL  CELLS 
BY  MICHAEL P.  BEVILACQUA, JORDAN  S.  POBER,  GERARD R. MAJEAU, 
RAMZI S. COTRAN,  AND  MICHAEL A. GIMBRONE, JR. 
From the Vascular Pathophysiology Laboratory, Department of Pathology, Brigham and 
Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115 
Vascular endothelium in situ normally acts to inhibit coagulation and throm- 
bosis (reviewed in reference 1). However, recent observations suggest that under 
certain  circumstances  endothelial  cells  may  actively  promote  coagulation  by 
various mechanisms (2-7).  For example, human endothelial cells in vitro (2-4), 
like monocytes and macrophages (8, 9), can be induced to express a tissue factor- 
like procoagulant activity (PCA), thereby activating coagulation via the extrinsic 
pathway.  Since  inflammatory and  immunological  processes  in  vivo  are  often 
associated with localized or disseminated intravascular coagulation, we hypothe- 
sized  that  soluble  mediators  produced  during  these  processes  might  induce 
endothelial cell expression of PCA, thus modulating the thrombogenicity of the 
blood-vascular wall interface. 
IL-1  is a  potent intercellular mediator involved in inflammatory and immu- 
nological  responses.  It  is  elaborated  by  monocytes and  macrophages  during 
antigen  presentation  and  in  response  to  a  variety  of other  stimuli  including 
endotoxin. Although originally defined as a  co-stimulator of thymocyte prolif- 
eration and an  activator  of T  lymphocytes, IL-1  also acts  upon  nonlymphoid 
target cells to produce multiple biological effects, including fever, elaboration of 
acute phase  reactants, and fibroblast proliferation (reviewed in references  10- 
12).  In this report,  we demonstrate that purified human monocyte-derived IL- 
l  is a  potent inducer of a  tissue factor-like PCA in cultured human endothelial 
cells. 
Materials and Methods 
Cell Cultures.  Primary cultures of human umbilical vein endothelial cells (HEC) were 
established in  Medium  199  (M.A.  Bioproducts, Walkersville,  MD) with 20%  fetal calf 
serum (FCS, Hyclone, Logan, UT or Gibco, Grand Island, NY) as previously described 
(13),  and several strains were serially passaged (up to subculture 30 at  1:3 split ratios) 
using Endothelial Cell Growth Supplement (50-100 t~g/ml; a gift of Dr. T. Maciag, Meloy 
Laboratories,  Springfield,  VA)  and  porcine  intestinal  heparin  (50-100  ug/ml,  Sigma 
Chemical Co., St. Louis, MO). For experimental use, freshly isolated or subcultured HEC 
were plated (4.0  ×  104 celts/well)  and grown to confluence (3-7 d) in  16-mm diameter 
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wells (Cluster 24,  Costar, Cambridge,  MA) coated with plasma fibronectin (1  ug/cm  2, 
Meloy Laboratories). 
IL-1 Preparations.  Human IL-1, isolated as a ~15,000-dalton polypeptide from Staph- 
ylococcus albus-stimulated  human monocyte supernatants by immunoabsorption (14) and 
Sephadex chromatography, was obtained from Genzyme Inc., Boston, MA. This material 
was provided in sterile 0.15  M NaCI  with 5%  FCS (IL-1  diluent) and was reported to 
contain 100 U/ml thymocyte co-stimulation activity, <1.0% T  cell growth factor, <1  U/ 
ml interferon, and undetectable endotoxin activity. Thymocyte co-stimulation activity was 
independently confirmed (courtesy of Dr. C. Reiss, Dana-Farber Cancer Institute, Boston, 
MA) and absence of endotoxin (<0.1 ng/ml) documented by Limulus assay (Sigma) in our 
laboratory. 
Experimental Procedure.  HEC monolayers were washed three times with 10% FCS in 
RPMI-1640 (RPMI, M.A. Bioproducts), incubated for up to 60 min at 37°C, and washed 
again to remove growth media. IL-1, endotoxin in the form of lipopolysaccharide (LPS, 
E. coli 0111.B4, Difco Laboratories, Detroit, MI), or control media (IL-1  diluent, Gen- 
zyme, or  10% FCS-RPMI) were added to each 16-mm well in a final volume of 0.5 ml 
10%  FCS-RPMI. In certain experiments, cycloheximide and actinomycin D (Sigma) also 
were included. After incubation (37°C, 5% COs) for up to 28 h, each well was washed 
twice with 0.5 ml Dulbecco's phosphate buffered saline (DPBS). 
Evaluation of PCA.  A  standard one-stage clotting (plasma  recaicification) assay was 
performed, essentially as described (9), at 37 °C using glass tubes containing 100 #1 citrated 
normal donor platelet-poor plasma, or coagulation Factor VII-, IX-, or X-deficient plasma 
(George King Bio-Medical, Overland Park, KS), to which 100 #1 cell lysate (frozen-thawed 
three  times,  scrape  harvested)  and  100  #1  CaCI2 (30  mM)  were  added.  In  certain 
experiments, PCA was assayed directly in the culture wells on intact, viable  or frozen- 
thawed monolayers, using a  modified plasma recalcification technique (4,  15). To each 
well containing an intact or disrupted monolayer in 200 #1 DPBS, 200 #1 normal citrated 
plasma and 200 #1 30 mM CaCI~ were added, and the clotting time determined. Milliunits 
(mU) of PCA were defined by reference to standard curves (log-log plot) developed with 
rabbit brain thromboplastin (Sigma);  103 mU PCA corresponded to a clotting time of 20 
seconds in the standard assay with normal plasma. 
Results 
Purified  IL-I  Induces  Procoagulant  Activity  in  Cultured  HEC.  Unstimulated 
passaged  HEC  (subcultures  3-25;  5  strains)  demonstrated  low  levels  of total 
cellular PCA (27 +  3 mU/105 cells, mean +  SE, 15 experiments) in our standard 
clotting assay. After treatment with human monocyte-derived IL-1  (10  U/ml) 
for 4-6  h, cellular PCA was dramatically increased (271  __+ 38 mU/105 cells, 6 
experiments). Negligible PCA (<2 mU/10 ~ cells) was liberated into the media of 
control or IL-1-treated HEC cultures. IL-1 preparations did not contain detect- 
able PCA. Fig.  1 a  illustrates the concentration dependence of IL-1 induction of 
HEC-PCA. Stimulation was observed with 0.5-1.0 U/ml IL-1 and was maximum 
(4-15  times control, 4  experiments) at ~ 10  U/ml. The majority of our experi- 
ments were  carried  out with  immunoaffinity purified,  monocyte-derived IL-1 
(Genzyme,  Inc.);  however,  monocyte-derived  IL-1  prepared  by alternate  bio- 
chemical  methods  (kindly  provided  by  K.  Matsushima  and J. J.  Oppenheim, 
National Cancer Institute, Frederick, MD) had comparable HEC-PCA-inducing 
activity (126-135%  of that of immunoaffinity-purified preparations at 5-10  U/ 
mi, 3 experiments). 
Significant increases in HEC-PCA (total cellular) were detectable following 1 
h  of continuous exposure to 5  U/ml IL-1  (Fig.  1 b).  Activity peaked between 3 
and 6 h and declined to near basal levels by 24 h. Addition of fresh IL-1 at 24 h 
gave  negligible  restimulation  by  28  h, suggesting  that  the  HEC  had  become 620  BEVILACQUA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE  1.  (a) Concentration dependence of IL-1  induction of total cellular procoagulant 
activity in passaged human endothelial cells. PCA was assayed in freeze-thaw HEC lysates after 
4 h  incubation with the indicated concentrations of IL-1. Each point represents mean values 
from  duplicate cultures.  Similar results were  obtained  in  three additional experiments.  (b) 
Time  course  of  IL-1  induction  of total  cellular  procoagulant  activity  in  passaged  human 
endothelial cells. Replicate cultures were incubated in  10% FCS-RPMI with 5  U/ml IL-1 for 
up to 28 h (0). At 24 h control (&) and IL-1 treated (I) wells were stimulated with fresh IL-1 
(5  U/ml) for 4  additional h.  Each point represents the mean of duplicate cultures. Similar 
results were found in two additional experiments. 
refractory. Treatment with cycloheximide or actinomycin D (5 t~g/ml) essentially 
blocked (>95% inhibition) IL-1  induction (4 h, 5  U/ml) of HEC-PCA, without 
causing microscopically detectable cell toxicity. 
In addition to passaged umbilical vein endothelial cells, IL-1  also enhanced 
total cellular PCA in primary umbilical vein endothelial cultures (8.7 _4- 1.1 times 
control, mean +  SE,  5 experiments). However, IL-1  (10 U/ml, 4-6 h) did not 
stimulate total cellular PCA in a human dermal fibroblast strain (A1F21, basal 
PCA  511  mU/105  cells,  kindly provided  by  Dr. J.  Rheinwald,  Dana-Farber 
Cancer Institute) and in a human lymphoblastoid B cell line (basal PCA 2 mU/ 
105 cells, kindly provided by Dr. J. L. Strominger, Harvard University). 
Endotoxin has been reported to induce PCA in primary HEC cultures (3, 4). 
We confirmed this observation and found a  similar result in  serially passaged 
HEC. In comparison, IL-1 consistently induced more HEC-PCA than did endo- 
toxin (data not shown). Furthermore, IL-1  induction of HEC-PCA appeared to 
be  independent of endotoxin  in  that:  (a)  our  IL-1  preparations  were  free  of 
endotoxin by Limulus assay; and (b) heat treatment (80°C,  15 min) completely 
abolished both the PCA-inducing activity (96 __. 4% inhibition, mean _  SE, four 
experiments) and the thymocyte co-stimulating activity (100%  inhibition,  one 
experiment) of IL-I, but did not affect the PCA-inducing activity of endotoxin 
in our system (-4 +  3% inhibition, three experiments). 
Cell Surface Expression of HEC-PCA.  Unstimulated intact  HEC  monolayers 
expressed  little  or  no  surface-available  PCA  (0-2  mU  PCA/105  cells,  four 
experiments), consistent with previous observations (3,  4,  15).  However, incu- 
bation  of HEC  monolayers with  IL-1  (10  U/ml,  4  h,  37°C)  resulted  in  the 
development of a  highly clot-promoting surface (94 mU PCA/10 ~ cells, Table 
I).  This  surface-available PCA  represented >70%  of the  total  HEC-PCA,  as 
determined by freeze-thaw lysis of replicate cultures. In contrast, IL-1  did not 
substantially affect the constitutively high surface PCA associated with human BEVILACQUA ET  AL.  BRIEF  DEFINITIVE REPORT 
TABLE  I 
Cell Surface Expression of Endothelial Procoagulant Activity 
Treatment 
Endothelial procoagulant activity (mU/10  5 cells) 
Intact mono-  % Surface 
layer  Cell lysates  expression 
Control  1  21  5 
Interleukin 1 
2.5 U/ml  29  63  46 
10 U/ml  94  131  71 
Endotoxin 
10 #g/ml  14  42  33 
Replicate HEC cultures in  16-ram wells were incubated for 4  h  in  10% 
FCS-RPMI with  IL-1  or endotoxin (LPS, E.  coli 0111 .B4) and assayed, 
either as intact monolayers (surface-available PCA), or as cell lysates (total 
cellular PCA). Data represent means from duplicate wells in two separate 
experiments. 
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dermal fibroblast cultures (240 mU/105 cells). IL-1 treatment (up to 20 U/ml, 4 
h) did not result  in  loss of cellular  integrity  in  HEC monolayers as judged by 
11~In release (16) (-7 to 4% specific release, two experiments) and trypan blue 
exclusion (96-103% of control,  10 experiments). 
Characterization  of IL-l-induced  Endothelial  Procoagulant Activity.  IL-l-in- 
duced total cellular and cell surface HEC-PCA were not demonstrable in coag- 
ulation  Factor  X-deficient  plasma  (clotting  times  >450  and  >600  seconds, 
respectively), and were reduced to control  HEC-PCA levels when measured in 
Factor VII-deficient plasma (Table II). Total cellular PCA was also tested in a 
Factor IX-deficient plasma in which IL-l-treated HEC caused a marked reduc- 
tion  of clotting  time  when  compared  with  control  HEC.  Treatment  of HEC 
lysates and intact monolayers with a  goat anti-human  apoprotein  III antiserum 
(3) (kindly provided by Prof. H. Prydz, Research Institute for Internal Medicine, 
University of Oslo, Oslo, Norway) substantially diminished  IL-l-induced  PCA 
(90% and 100% inhibition, respectively, Table II), while treatment with a control 
goat antiserum  had  no effect.  In  addition,  IL-l-induced  PCA was completely 
abolished  by treatment  of HEC  lysates  with  phospholipase  C  (Bacillus  cereus, 
Sigma; 6 U/ml,  10 min at 37 °C). These data suggest that most, if not all, of the 
IL-l-induced  HEC-PCA acts via the extrinsic pathway (Factor VII dependent) 
and is immunochemically related to or identical with tissue factor. 
Discussion 
This study defines monocyte-derived IL-1 as a potent inducer of procoagulant 
activity in HEC. Cultured HEC contained low levels of PCA, and expressed little 
or no activity at  their  surface.  Incubation  of HEC  with  IL-1  led to a  marked 
increase  in  total  cellular  PCA  which  was  dependent  upon  de  novo  protein 
synthesis.  Continuous  exposure  to  IL-1  resulted  in  a  transient  PCA elevation, 
followed by hyporesponsiveness to fresh  IL-1. In vivo, this pattern  of response 
might serve to limit the extent of endothelial-mediated intravascular coagulation. 
IL-1 also induced a dramatic increase in PCA expression on the surface of intact 
monolayers, suggesting that this activity would be accessible to the plasma clotting 622  BEVILACQUA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  II 
Characterization of IL-1-Stimulated Endothelial Procoagulant 
Activity 
Net I L- 1-induced procoagulant activity 
(m U/105 cells)* 
Endothelial pro-  Factor-deficient  Antibody treatment 
coagulant activity  Normal  plasmas 
plasma  VII  X  1X  Control  Anti-apoprotein 
III 
Total cellular*  140  -6  0  119  133  14 
Cell surface*  66  0  0  ND  57  0 
Net IL-l-induced PCA =  IL-l-induced PCA -  Control PCA. 
Determined  in  separate  experiments,  using  normal  and  coagulation 
factor-deficient plasmas.  Milliunits (mU)  of activity  were  established 
from standard curves developed  with a  single source of rabbit tissue 
thromboplastin.  PCA  of cell  lysates and  intact monolayers  were  also 
evaluated in  normal  human plasma after treatment with a  goat anti- 
human  apoprotein  III  antiserum  and  a  control  (anti-human gamma 
globulin) goat antiserum, essentially as described (3), using final antisera 
dilutions of 1:200 for 20 min at 37°C  followed by washing for intact 
monolayers, and for 15 min at 37°C and 1 h at 4°C for cell lysates. 
system in vivo. Data obtained with coagulation factor-deficient plasma and an 
anti-apoprotein I II antiserum suggested that most, if not all, of the IL-1-induced 
HEC-PCA measured in intact cell monolayers and cell lysates was tissue factor- 
like. Preliminary experiments with purified human factors X and VIIa (generous 
gifts of Dr. David Stern, Columbia University and Dr. Walter Kisiel,  University 
of Washington) further support this conclusion (unpublished observations). IL- 
l-induced HEC  total  cellular and surface-available procoagulant activity may 
reflect increases in the amount and/or activity of tissue factor-like molecules. 
However, given the multiple potential roles of endothelial cells in coagulation 
(1-7), IL-1 effects on other procoagulant mechanisms cannot be ruled out. 
Recently, it has been reported that primary cultures of HEC develop tissue 
factor-like procoagulant activity during coculture with peripheral blood lympho- 
cytes and certain leukocyte cell lines (3). Furthermore, it has been well established 
that monocytes and macrophages produce procoagulant activity in response to a 
variety of stimuli, some of which require lymphocyte cooperation (8, 9).  These 
observations suggest that interactions among lymphocytes, monocytes, and en- 
dothelial cells may be involved in the development of intravascular coagulation 
in certain pathological settings. Our data indicate that the elaboration of IL-1 
and its action on vascular endothelium may be central to this process. 
Summary 
Human monocyte-derived  interleukin 1 (IL-1) was found to be a potent inducer 
of procoagulant activity in cultured human vascular endothelium. IL-l-induced 
human  umbilical  vein  endothelial  cell  procoagulant  activity  (HEC-PCA)  was 
transiently expressed, manifest in  intact cell monolayers, and required protein 
synthesis.  Data  obtained  with  coagulation  factor-deficient plasma  and a  goat 
anti-human apoprotein  III antiserum suggested that most, if not all,  of IL-1- 
induced endothelial cell procoagulant activity is tissue factor-like. IL-1 induction BEVILACQUA  ET  AL.  BRIEF  DEFINITIVE REPORT  623 
of HEC-PCA may be important in the pathogenesis of intravascular coagulation 
in a  variety of immunological and inflammatory conditions. 
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